MHC Class II HLA-DP/DQ/DR antibody

Catalog No. ABIN316913

The Mouse Monoclonal anti-MHC Class II HLA-DP/DQ/DR antibody is suitable to detect MHC Class II HLA-DP/DQ/DR in samples from Human. It has been validated for FACS.

Quick Overview for MHC Class II HLA-DP/DQ/DR antibody (ABIN316913)

Target: MHC Class II HLA-DP/DQ/DR (HLA-DP/DQ/DR)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MHC Class II HLA-DP/DQ/DR antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: Bu26

Product Details anti-MHC Class II HLA-DP/DQ/DR Antibody

Characteristics: Synonyms: HLA-DR, HLA-DQ, HLA-DP, MHC class II antigen DP, DR, DQ, HLA class II histocompatibilityantigen DP

Purification: Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

Isotype: IgG1

Application Details

Application Notes: Flow Cytometry: 1/100 - 1/200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0mg/mL

Buffer: Phosphate buffered saline pH 7.4 containing 0.09 % Sodium Azide (NaN3)

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch. Caution: (A full Health and Safety assessment is available upon request) This product containsSodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled bytrained staff only.

Expiry Date: 12 months

Target Details for MHC Class II HLA-DP/DQ/DR

Target: MHC Class II HLA-DP/DQ/DR (HLA-DP/DQ/DR)

Alternative Name: HLA Class II DP, DR, DQ

Background: Synonyms: DQ, DR, HLA class II histocompatibility antigen DP, HLA-DP, HLA-DQ, HLA-DR, MHC class II antigen DP

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response